LCLianying Cheng

Lianying Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lianying Cheng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Dehao Du

    Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Han Zhang

    School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Jiayu Tian

    Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Linlan Zhou

    Department of Integrated Traditional Chinese and Western Medicine, Sci-Tech Innovation Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Tingdan Zhang

    Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Xiaofeng Rong

    Department of Integrated Traditional Chinese and Western Medicine, Sci-Tech Innovation Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

    1 shared publication

Latest Publications

  • Open Access

    Investigating the Mechanism of Emodin in Rheumatoid Arthritis Through the HIF-1α/NLRP3 Pathway and Mitochondrial Autophagy

    by Dehao Du, Linlan Zhou, Jiayu Tian, Lianying Cheng, Han Zhang, Yifu Tang, Zexuan Qiu, Tingdan Zhang, Xiaofeng Rong

    In this study, we investigated the inhibitory effects of emodin on pyroptosis in rheumatoid arthritis (RA) synovial cells by modulating the HIF-1α/NLRP3 inflammasome pathway and mitochondrial autophagy. By employing a chemically induced hypoxia model with CoCl2, we established experimental groups including normal control, model group, and emodin-treated groups at different concentrations (5 μM, 10 μM, and 20 μM). We optimized the CoCl2 concentration via CCK-8 assay to ensure cell viability. ELISA, Western blotting, transmission electron microscopy, and immunofluorescence were employed to assess HIF-1α, IL-1β, and IL-18 levels, pyroptosis-related proteins, autophagy markers, and NLRP3 fluorescence intensity. Statistical analysis revealed that increased CoCl2 concentrations led to a significant cell viability reduction (p < 0.05), with 300 μM CoCl2 causing ~50% inhibition at 24 h. Transmission electron microscopy confirmed autophagosome formation in emodin-treated groups, while Western blotting showed dose-dependent downregulation of HIF-1α, NLRP3, BNIP3, and related proteins. Immunofluorescence revealed reduced NLRP3 fluorescence intensity with increasing emodin doses (p < 0.05), alongside dose-dependent cell viability recovery (p < 0.05). Our findings demonstrate that emodin alleviates RA synovitis through dual mechanisms: inhibition of mitochondrial autophagy to regulate the balance between mitochondrial autophagy and pyroptosis, and suppression of HIF-1α/NLRP3-mediated pyroptosis signaling, thereby reducing IL-1β and IL-18 release and inhibiting synovial cell proliferation. This study provides innovative approaches for targeted RA therapy.